Related Experiment Video
Updated: Apr 8, 2026
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
PD-L1 and Survival in Solid Tumors: A Meta-Analysis
1Department of Thoracic Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China; Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences), Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China.
Programmed death-ligand 1 (PD-L1) overexpression is linked to poorer survival outcomes in solid tumors. This meta-analysis confirms PD-L1
Area of Science:
- Oncology
- Immunology
- Biomarker Research
Background:
- Immune checkpoint inhibitors targeting PD-L1/PD-1 are under development.
- The prognostic significance of PD-L1 expression in solid tumors remains controversial.
Purpose of the Study:
- To conduct a systematic review and meta-analysis.
- To investigate the prognostic value of PD-L1 expression in human solid tumors.
Main Methods:
- Systematic search of electronic databases for studies on PD-L1 expression and overall survival (OS).
- Meta-analysis using a random-effect model to pool odds ratios (ORs).
- Analysis of heterogeneity and publication bias.
Main Results:
- Included 3107 patients from 28 studies; median PD-L1 overexpression was 52.5%.
- PD-L1 overexpression correlated with worse 3-year OS (OR=2.43) and 5-year OS (OR=2.23).
- Associated with worse OS in esophageal, gastric, hepatocellular, urothelial, and colorectal cancers.
Conclusions:
- PD-L1 expression indicates poorer survival in solid tumors.
- Prognostic correlations vary significantly across different tumor types.
- Further research is needed to clarify PD-L1's clinical utility in prognosis and treatment decisions.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
